Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Names New CEO as Prepares to Accelerate Efforts

NEW YORK, May 17 – Nanogen announced Thursday that Vance Randy White had been appointed chief executive officer and would replace company founder Howard Birndorf, who will remain chairman of the company’s board.

The move appears to signal Nanogen’s efforts to accelerate its move into the clinical diagnostics arena.

"We welcome Randy and believe that his hands-on experience in clinical assay development and insight into the clinical markets will be an invaluable asset to Nanogen as it explores its opportunities to make its technology available to clinical diagnostics customers, such as hospitals and reference labs,” Birndorf said in a statement.

“We look forward to Randy's leadership and proven success to drive Nanogen's commercialization efforts of our products,” he said.

A representative of the San Diego-based company was not immediately available for comment.

White was most recently executive vice president of technical operations at American Medical Laboratories, a clinical reference laboratory.

Nanogen manufactures tthe NanoChip Cartridge and the NanoChip Molecular Biology Workstation.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.